99% Purity retatrutide Powder tiezepatide Raw Powder weight loss peptides

  Product Detail  

Here’s a clear scientific overview of the peptide Retatrutide:

Retatrutide (LY-3437943)

General Information

• Type: Synthetic peptide (39 amino acids, modified)

• CAS Number: 2381089-83-2

• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈

• Molecular Weight: ~4731 Da

• Structure: Includes aminoisobutyric acid (Aib) substitutions and a fatty acid chain to improve stability and half-life (~6 days).

Mechanism of Action

Retatrutide is a triple agonist peptide that activates:

• GLP-1 receptor (GLP-1R) → enhances insulin release, suppresses appetite, slows gastric emptying.

• GIP receptor (GIPR) → supports insulin secretion and improves insulin sensitivity.

• Glucagon receptor (GCGR) → increases energy expenditure and modulates lipid/glucose metabolism.

This unique multi-target action makes it more potent for weight loss and metabolic control than single or dual agonists.

Potency (human receptor EC₅₀ values)

• GIPR: ~0.064 nM (very high potency)

• GLP-1R: ~0.775 nM

• GCGR: ~5.79 nM

Clinical Development

• Indications:

  • Obesity (primary target)

  • Type 2 diabetes (secondary target)

• Phase 2 Trial Results (2023–2024):

  • Up to 24.2% mean weight loss in 48 weeks (12 mg dose, weekly).

  • Strong glucose control improvements.

• Current Status (2025): In Phase 3 clinical trials.

Pharmacokinetics

• Administration: Subcutaneous injection

• Half-life: ~6 days (enables once-weekly dosing)

Key Advantages

• Greater weight-loss efficacy than GLP-1 agonists (like semaglutide).

• Multi-pathway mechanism may improve fat metabolism and insulin resistance beyond dual agonists like tirzepatide.

📌 In short: Retatrutide is a next-generation peptide drug candidate, a triple incretin receptor agonist, showing record levels of weight reduction and strong glucose control, now in late-stage clinical trials.